BioMarin Pharmaceutical Inc. (BMRN)

111.21
2.88 2.66
NASDAQ : Health Technology
Prev Close 108.33
Open 108.34
Day Low/High 107.39 / 112.39
52 Wk Low/High 62.88 / 109.51
Volume 1.94M
Avg Volume 1.74M
Exchange NASDAQ
Shares Outstanding 180.84M
Market Cap 19.42B
EPS -0.10
P/E Ratio 170.46
Div & Yield N.A. (N.A)
Stocks Love Fed's Bond Addiction

Stocks Love Fed's Bond Addiction

Stocks are moving higher as the Fed said it will keep buying bonds. Rite Aid is up and Pier One is down, Take Two is a steal.

Biomarin downgraded at Stifel

Biotech's Next Big Thing: BioMarin

Biotech's Next Big Thing: BioMarin

BioMarin's R&D update next Tuesday will be the biggest thing in biotech in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet.

BioMarin estimates raised at UBS

Mad Money Uncovered: ASCO

Mad Money Uncovered: ASCO

Jim Cramer looks at stocks moving on cancer-fighting develompents, in a discussion with Mad Money Research Director Nicole Urken

Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts

Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts

Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken

A Deep Post-Decline Analysis Part 2

A Deep Post-Decline Analysis Part 2

Stocks that defy correction and those ripe for correction.

The Beat Goes On

The Beat Goes On

The slow, steady push higher continues.

The Next Big Thing In Biotech: BIO CEO Conference

The Next Big Thing In Biotech: BIO CEO Conference

Adam Feuerstein, Sr. Columnist for TheStreet, says the BIO CEO Conference is the next big thing in biotech.

Trick of the Trading

Trick of the Trading

It's the bulls' turn to shine.

Biomarin upgraded at Stifel

The Next Big Thing in Biotech: J.P. Morgan Conference

The Next Big Thing in Biotech: J.P. Morgan Conference

Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.

The Next Big Thing In Biotech: Ligand, BioMarin & Sangamo

The Next Big Thing In Biotech: Ligand, BioMarin & Sangamo

Adam Feuerstein, Sr. Columnist for TheStreet, says Ligand, BioMarin and Sangamo are the next big things to watch in biotech.

Biomarin downgraded at Deutsche

Biomarin rated new Buy at ThinkEquity

BioMarin rated new Buy at UBS

Biomarin upgraded at Brean

Waiting for the Pattern to Break

Waiting for the Pattern to Break

Trading on the S&P 500 has remained tightly contained so far.

Biotech Is Booming

Biotech Is Booming

Despite the solid performance so far this year, there's still time to get on board and ride the profit train.